Print Page  Close Window

Events & Presentations
Upcoming Events
There are currently no events scheduled.
Past Events
08/08/17 5:00 p.m. ET
Q2 2017 Bellicum Pharmaceuticals Earnings Conference Call
Click here for webcast
06/23/17
Bellicum Pharmaceuticals Inc at European Hematology Association Presentation Details

Oral Presentation - Presidential Symposium: “BPX-501 Donor T-Cell Infusion (with Inducible Caspase 9 Suicide Gene) Facilitates HLA Haploidentical Stem Cell Transplant in Children with both Hematological Malignancies and Non-Malignant Conditions”
Session Title: Presidential Symposium
Date: Friday, June 23
Session Time: 3:45 – 4:00 PM CEST
Location Hall A
Abstract Code: S146

Oral Presentation: “Impact of Post-Transplant Infusion of Donor T-Cells Genetically Modified with Inducible Caspase 9 Suicide Gene (BPX-501 Cells) on Children with Leukemia Given Alpha-Beta T-Cell Depleted Haplo-HSCT”
Session Title: Stem cell transplantation – Clinical 1
Session Name: 732.Clinical Allogeneic Transplantation: Results: Predicting Outcome
Date: Saturday, June 24
Session Time: 5:00 – 5:15 PM CEST
Location: Room N103
Abstract Code: S495

Poster Presentation: “The Use of BPX-501 Donor T-Cell Infusion (with Inducible Caspase 9 Suicide Gene) Together with HLA-Haploidentical Stem Cell Transplant to Treat Children with Hemoglobinopathies and Erythroid Disorders”
Session Title: Stem cell transplantation – Clinical 1
Date: Friday, June 23
Time: 5:15 – 6:45 PM CEST
Session Time: Poster Area (Hall 7)

06/14/17 10:00 a.m. CT
Bellicum Pharmaceuticals Inc Annual Shareholder Meeting For holders as of: April 17, 2017
Location: Bellicum Pharmaceuticals, Inc.
2130 West Holcombe Blvd., Suite 800
Houston, TX 77030
06/07/17 2:00 p.m. ET
Bellicum Pharmaceuticals Inc at Jefferies 2017 Global Healthcare Conference
Click here for webcast
05/10/17
through
05/12/17
American Society of Gene & Cell Therapy (ASGCT) 20th Annual Meeting

Poster Presentation: “A dual-switch platform to orthogonally control CAR-T cell efficacy and safety with two non-immunosuppressive chemical inducers of protein dimerization”
Date/Time:Wednesday, May 10, 2017 from 5:30 PM – 7:30 PM EDT

Oral Abstract Presentation: “Dual-Switch CAR-T Cells: Dual Molecular Switches to Control Activation and Elimination of CAR-T Cells to Target CD123+ Cancer"”
Session Name: 345 “Preclinical Optimization of Immunotherapies”
Date/Time: Friday, May 12, 2017 5:00 PM – 5:15 PM EDT

Location: Washington, DC
05/03/17 2:10 p.m. ET
Bellicum Pharmaceuticals Inc at Deutsche Bank 42nd Annual Health Care Conference
Click here for webcast
04/27/17 3:15 p.m. ET
Bellicum Pharmaceuticals Inc at ARM's Cell & Gene Therapy Investor Day
Click here for webcast
04/04/17
AACR Annual Meeting 2017

"Dual-switch HER2 CAR-T cells: Small molecule-regulated GO and STOP switches to target solid cancer in vivo"

"Dual-switch TCR: A two-ligand system to control PRAME TCR-modified T cell proliferation and death using inducible MyD88/CD40 and caspase-9"

03/15/17 4:20 p.m. ET
Bellicum Pharmaceuticals Inc at Barclays Global Healthcare Conference
Click here for webcast
03/13/17 5:00 p.m. ET
Q4 YE 2016 Bellicum Pharmaceuticals Earnings Conference Call
Click here for webcast
02/22/17
2017 BMT Tandem Meetings

VIEW POSTER

12/05/16 12:15 p.m. PT
Bellicum ASH Investor & Analyst Lunch
Click here for webcast
12/03/16
through
12/05/16
ASH Presentations on Bellicum Programs

BPX-501:

Oral Presentation:Outcome of Children with Primary Immune-Deficiencies (PIDs) Enrolled in a Phase I-II Trial Based on the Infusion of BPX-501 Donor T Cells Genetically Modified with a Novel Suicide Gene (Inducible Caspase 9, iC9) After T-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (Haplo-HSCT)
Abstract Number: 72
Session Name: 732.Clinical Allogeneic Transplantation: Results: Predicting Outcome
Date: Saturday, December 3, 2016
Session Time: 7:30 AM - 9:00 AM PST
Presentation Time: 8:45 AM PST

Poster Presentation: Clinical Outcome and Immune Recovery after Adoptive Infusion of BPX-501 Cells (Donor T Cells Transduced with iC9 Suicide Gene) in Children with Hemoglobinopathies and Diamond-Blackfan Anemia Given a/b T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (HSCT)
Abstract Number: 2286
Session Name: 732.Clinical Allogeneic Transplantation: Results: Poster I
Date: Saturday, December 3, 2016
Presentation Time: 5:30 PM - 7:30 PM PST

Poster Presentation:T-Cell Depleted HLA-Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (Haplo-HSCT) Followed by Donor Lymphocyte Infusion with T Cells Transduced with the Inducible Caspase 9 (iC9) Suicide Gene in Children with Hematological Malignancies
Abstract Number: 4683
Session Name: 732.Clinical Allogeneic Transplantation: Results: Poster III
Date: Monday, December 5, 2016
Presentation Time: 6:00 PM - 8:00 PM PST

CAR-T Program: (CD123 CARs)

Poster Presentation:Inducible MyD88/CD40 (iMC) Costimulation Provides Ligand-Dependent Tumor Eradication by CD123-Specific Chimeric Antigen Receptor T Cells
Abstract Number: 4551
Session Name: 703.Adoptive Immunotherapy: Poster III
Date: Monday, December 5, 2016
Presentation Time: 6:00 PM – 8:00 PM PST

TCR Program: (PRAME and Bob-1 TCRs)

Poster Presentation: Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells and Improves Anti-Tumor Efficacy in Myeloma
Abstract Number: 4550
Session Name: 703.Adoptive Immunotherapy: Poster III
Date: Monday, December 5, 2016
Presentation Time: 6:00 PM – 8:00 PM PST

11/16/16 4:40 p.m. GMT
Bellicum Pharmaceuticals Inc at Jefferies 2016 London Healthcare Conference
Location: LondonGB
11/07/16 11:30 a.m. MT
Bellicum Pharmaceuticals Inc at Credit Suisse 25th Annual Healthcare Conference
Location: Scottsdale, AZ
09/27/16 10:00 a.m. ET
Bellicum Pharmaceuticals Inc at Ladenburg Thalmann 2016 Healthcare Conference
Location: New York City
09/09/16 9:30 a.m. ET
Bellicum Pharmaceuticals Inc at BioCentury 23rd Annual NewsMakers in the Biotech Industry Conference
Location: New York City
08/08/16 5:00 p.m. ET
Q2 2016 Bellicum Pharmaceuticals Inc Earnings Conference Call
06/15/16 10:00 a.m. CT
Bellicum Pharmaceuticals, Inc. Annual Shareholder Meeting
Location: Meeting Room, 8th Floor
Bellicum Pharmaceuticals, Inc.
2130 West Holcombe Blvd.
Houston, TX 77030
06/11/16 10:30 a.m. ET
Infusion of BPX-501 (donor T cells transduced with the iC9 suicide gene) after α/β T-cell depleted haplo-HSCT in children with acute leukemia: Preliminary results of a Phase I-II trial

EHA 2016 Oral Presentation

Presentation Title: “Infusion of BPX-501 (donor T cells transduced with the iC9 suicide gene) after α/β T-cell depleted haplo-HSCT in children with acute leukemia: Preliminary results of a Phase I-II trial”
Abstract Number: S523
Session Name: Stem cell transplantation - Clinical 1
Date: Saturday, June 11, 2016
Presentation Time: 4:30 PM - 4:45 PM CEST (10:30 AM – 10:45 AM EDT)

06/08/16 3:30 p.m. ET
Bellicum Pharmaceuticals Inc at Jefferies 2016 Global Healthcare Conference
Location: New York City, NY
06/05/16 8:00 a.m. CT
Enhanced efficacy and safety of Her2-targeted chimeric antigen receptor (CAR) T cells using MyD88/CD40 costimulation and iCaspase-9 suicide switch

ASCO 2016 Poster Presentation

Abstract Number: 3050
Poster Board: #372
Session Name: Developmental Therapeutics - Immunotherapy
Date: Sunday, June 5, 2016
Presentation Time: 8:00 AM - 11:30 AM CDT (9:00 AM – 12:30 PM EDT)

05/12/16 10:40 a.m. PT
Bellicum Pharmaceuticals Inc at Bank of America Merrill Lynch 2016 Health Care Conference
Location: Las Vegas, NV
04/18/16 9:00 a.m. ET
Late-Breaking Poster Presentation on TCR Product Candidate with Activation Switch at AACR 2016

Abstract Number: LB-084
Presentation Title:  “Go-TCR: Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T cells, Increasing Anti-Tumor Efficacy”
Presentation Date: Monday, April 18, 2016
Presentation Time: 8:00 a.m. -12:00 p.m. CDT
Location: New Orleans, LA

Supporting Materials: 
Download Event Supporting Material AACR 2016 GoTCR Presentation
04/04/16
through
04/05/16
Bellicum Pharmaceuticals, Inc. at 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain

"Presidential Symposium" Presentation: "Infusion of donor T cells transduced with inducible Caspase 9 (BPX-501 cells) is a safe and effective strategy to accelerate immune recovery inpatients with non-malignant disorders after T cell depleted haplo-HSCT."


Oral Presentation: "Inducible-caspase-9 transduced T cells after haplo-HSCT in children."

12/07/15 12:15 p.m. ET
Bellicum Pharmaceuticals Inc Investor and Analyst Event
Location: Hyatt Regency
Orlando, FL
12/05/15
through
12/08/15
Bellicum Pharmaceuticals Inc at American Society of Hematology (ASH) Annual Meeting

Seven abstracts accepted for presentation
Presentation details

Poster Presentation: “Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial”

  •  Abstract Number: 1931
  •  Session Name: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
  •  Date: Saturday, December 5, 2015
  •  Presentation Time: 5:30 PM - 7:30 PM EST
  •  View Poster

  • Poster Presentation: “Inducible MyD88/CD40 Enhances Proliferation and Survival of PRAME-Specific TCR-Engineered T Cells and Increases Anti-Tumor Effects in Myeloma”

    •  Abstract Number: 1886
    •  Session Name: 703. Adoptive Immunotherapy: Poster I
    •  Date: Saturday, December 5, 2015
    •  Presentation Time: 5:30 PM - 7:30 PM EST
    •  View Poster

    Poster Presentation: “Immune Reconstitution after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Phenotypic and Functional Results of a Phase I-II Trial”

    •  Abstract Number: 3093 Merli ASH 2015 poster
    •  Session Name: 703. Adoptive Immunotherapy: Poster II
    •  Date: Sunday, December 6, 2015
    •  Presentation Time: 6:00 PM - 8:00 PM EST
    •  View Poster

    Poster Presentation: “BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)”

    •  Abstract Number: 4299
    •  Session Name: 703. Adoptive Immunotherapy: Poster III
    •  Date: Monday, December 7, 2015
    •  Presentation Time: 6:00 PM - 8:00 PM EST
    • View Poster

    Poster Presentation: “Inducible MyD88/CD40 Allows Rimiducid-Dependent Activation to Control Proliferation and Survival of Chimeric Antigen Receptor-Modified T Cells”

    •  Abstract Number: 4295
    •  Session Name: 703. Adoptive Immunotherapy: Poster III
    •  Date: Monday, December 7, 2015
    •  Presentation Time: 6:00 PM - 8:00 PM EST
    • View Poster
12/02/15 12:30 p.m. ET
Bellicum Pharmaceuticals to Participate in Fireside Chat at the Piper Jaffray 27th Annual Healthcare Conference
11/19/15 9:00 a.m. ET
Bellicum Pharmaceuticals Inc at Jefferies 2015 Global Healthcare Conference
11/10/15 11:00 a.m. MT
Bellicum Pharmaceuticals Inc at 24th Annual Credit Suisse Healthcare Conference
10/01/15 2:45 p.m. ET
Bellicum Pharmaceuticals to present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
Location: New York, NY
08/13/15 5:00 p.m. ET
Q2 2015 Bellicum Pharmaceuticals Inc Earnings Conference Call
08/11/15 9:45 a.m. ET
Bellicum Pharmaceuticals at 2015 Wedbush PacGrow Healthcare Conference
Location: Le Parker Meridien Hotel
New York, NY
06/17/15 10:00 a.m. CT
Bellicum Pharmaceuticals Inc Annual Shareholder Meeting
Location: BioScience Research Collaborative (BRC) Building Auditorium
6500 Main Street
Houston, TX 77030
06/02/15 2:30 p.m. ET
Bellicum Pharmaceuticals Inc at Jefferies 2015 Global Healthcare Conference
Location: Grand Hyatt
New York City, NY
03/11/15 5:00 p.m. ET
Q4 2014 Bellicum Pharmaceuticals Inc Earnings Conference Call
02/11/15 2:40 p.m. ET
Bellicum Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference